Kyle Doherty

The frontline combination of ibrutinib with venetoclax was associated with complete response and durable remission for older patients with MCL.

Patients with mantle cell lymphoma and large clonal hematopoiesis clones had shorter progression-free and overall survival compared with those without clones.

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

FDA Issues Draft Guidance for Tissue Biopsies in Trials

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have progressed after PD-(L)1 therapy.

Retifanlimab plus carboplatin and paclitaxel boosted PFS for certain patients with recurrent or metastatic SCAC.

Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.

Adding blinatumomab to consolidation chemotherapy provided a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.

The clinical practice guideline from the American Society for Radiation Oncology focuses on the use of definitive and postoperative radiation therapy in patients with HPV-associated oropharyngeal squamous cell carcinoma.

Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.

Frontline treatment with ribociclib (Kisqali) plus endocrine therapy significantly improved progression-free survival (PFS) with superior tolerability compared with combination chemotherapy in clinically aggressive hormone receptor–positive, HER2-negative advanced breast cancer, according to findings from the phase 2 RIGHT Choice trial (NCT03839823) published in the Journal of Clinical Oncology. At a median follow-up of 37.0 months, patients who received ribociclib plus endocrine therapy (n =…

Patients with resectable esophageal cancer who underwent perioperative chemotherapy with docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT protocol) had a significant overall survival (OS) benefit compared with neoadjuvant chemoradiation (CROSS protocol), according to findings from the phase 3 ESOPEC trial (NCT02509286) shared via a news release during the 2024 ASCO Annual Meeting.1 At a median follow-up of 55 months, patients who received the FLOT protocol (n = 221) achieved a med…

Patients with stage IIB to IV melanoma who received adjuvant treatment with a CD8-positive T cell-targeted multipeptide vaccine (12MP) with a CD4-positive T cell-directed 6 melanoma-specific helper peptides (6MHP) vaccine exhibited prolonged survival compared with 12MP plus a nonspecific helper peptide vaccine from tetanus toxoid (tet), according to findings from a post-hoc analysis.1 The post-hoc analysis of a phase 2 clinical trial (NCT00118274) published in Nature Communications also showe…